Blood vessel maturation in human uveal Melanoma: Spatial distribution of neovessels and mature vasculature

Ophthalmic Research

Volumn 41, Issue 3, 2009, Pages 160-169

  Piña, Yolanda ^a   Cebulla, Colleen M ^a   Murray, Timothy G ^a,b   Alegret, Armando ^a   Dubovy, Sander R ^a   Boutrid, Hinda ^a   Feuer, William ^a   Mutapcic, Lejla ^a   Jockovich, Maria Elena ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Uveal melanoma; Vessel maturation

Indexed keywords

HEMATOXYLIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; ENUCLEATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; TUMOR VOLUME; UVEA MELANOMA; VASCULARIZATION; ADOLESCENT; BLOOD VESSEL; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; MELANOMA; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERICYTE; PROGNOSIS; UVEA TUMOR; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; EYE ENUCLEATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MELANOMA; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROGNOSIS; UVEAL NEOPLASMS;

EID: 62849105876     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209670     Document Type: Article

References (65)

1. Damato B: Developments in the management of uveal melanoma. Clin Exp Ophthalmol 2004;32:639-647.
2. Parkin DM, Muir CS: Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 1992; 120:45-173.
3. Kilic E, Stijnen T, de Jong PT, Mooy CM, Eijkenboom WM, Ringens PJ, Luyten GP: Reduced melanoma-related mortality in uveal melanoma by preenucleation radiotherapy. Arch Ophthalmol 2005; 123:1363-1367.
4. Kujala E, Makitie T, Kivela T: Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44:4651-4659.
5. Zimmerman LE, McLean IW: Do growth and onset of symptoms of uveal melanomas indicate subclinical metastasis? Ophthalmology 1984;91:685-691.
6. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC: The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 1992;23:1298-1305.
7. McLean IW, Saraiva VS, Burnier MN Jr: Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004;39: 343-350.
8. Lattman J, Kroll S, Char DH, Ghazvini S, Frigillana H, O'Brien JM, Elbakri HR: Cell cycling and prognosis in uveal melanoma. Clin Cancer Res 1995; 1:41-47.
9. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP: A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110:245-250.
10. Seddon JM, Albert DM, Lavin PT, Robinson N: A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101:1894-1899.
11. Shammas HF, Blodi FC: Orbital extension of choroidal and ciliary body melanomas. Arch Ophthalmol 1977;95:2002-2005.
12. McLean IW, Foster WD, Zimmerman LE: Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982;13:123-132.
13. Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, Friedenberg GR: Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol 1985;99:282-290.
14. Shammas HF, Blodi FC: Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 1977;95:63-69.
15. McLean IW, Ainbinder DJ, Gamel JW, McCurdy JB: Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 1995; 102: 1060-1064.
16. Makitie T, Summanen P, Tarkkanen A, Kivela T: Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:1414-1421.
17. Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999;40:2471-2480.
18. Ziemssen F, Wegner R, Wegner J, Tatar O, Susskind D, Gelisken F, Rohrbach M, Bartz-Schmidt KU, Grisanti S: Analysis of neovas-culature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endo-thelium? Graefes Arch Clin Exp Ophthalmol 2006;244:1124-1131.
19. Chen X, Maniotis AJ, Majumdar D, Peer J, Folberg R: Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci 2002;43:2533-2539.
20. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC: Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19:22-28.
21. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003;9:653-660.
22. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-835.
23. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
24. Rosenblatt MI, Azar DT: Anti-angiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol 2006;21:151-160.
25. Stitt AW, Gardiner TA: Anti-angiogenic therapy for uveal melanoma - more haste, less speed. Br J Ophthalmol 2002;86:368-369.
26. Yang H, Grossniklaus HE: Combined im-munologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 2006; 31:557-562.
27. Clark AF, Mellon J, Li XY, Ma D, Leher H, Apte R, Alizadeh H, Hegde S, McLenaghan A, Mayhew E, D'Orazio TJ, Niederkorn JY: Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999;40:2158-2162.
28. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-410.
29. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295.
30. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W: Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci 2006;47:1264-1268.
31. Jockovich ME, Bajenaru ML, Pina Y, Suarez F, Feuer W, Fini ME, Murray TG: Retino-blastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Invest Ophthalmol Vis Sci 2007;48:2476-2482.
32. Ozerdem U: Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse. Ophthalmic Res 2006;38: 251-254.
33. Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S: Mi-crovessel count predicts survival in uveal melanoma. Cancer Res 1996;56:2900-2903.
34. Folberg R, Hendrix MJ, Maniotis AJ: Vascu-logenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156:361-381.
35. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Peer J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-752.
36. Folberg R, Chen X, Boldt HC, Peer J, Brown CK, Woolson RF, Maniotis AJ: Microcircula-tion patterns other than loops and networks in choroidal and ciliary body melanomas. Ophthalmology 2001; 108:996-1001.
37. Niederkorn JY: Enucleation-induced metastasis of intraocular melanomas in mice. Ophthalmology 1984;91:692-700.
38. Laitinen L: Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 1987; 19:225-234.
39. Nehls V, Drenckhahn D: Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol 1991;113:147-154.
40. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410-3415.
41. Fonsatti E, Maio M: Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2004;2:18.
42. Thorpe PE, Burrows FJ: Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995;36:237-251.
43. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n = 905). Br J Cancer 2004; 90:1216-1221.
44. Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L, Kumar S: Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006;37: 861-866.
45. Erdem O, Taskiran C, Onan MA, Erdem M, Guner H, Ataoglu O: CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol 2006;103:1007-1011.
46. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003;88:1424-1431.
47. Marioni G, Ottaviano G, Giacomelli L, Staffieri C, Casarotti-Todeschini S, Bonandini E, Staffieri A, Blandamura S: CD105-assessed micro-vessel density is associated with malignancy recurrence in laryngeal squamous cell carcinoma. Eur J Surg Oncol 2006; 32: 1149-1153.
48. Martone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L, Pruneri G, Bellone G, CortesinaG: Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol 2005;41:147-155.
49. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004; 17:197-203.
50. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA: Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 2003; 111:1011-1018.
51. Straume O, Akslen LA: Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159:223-235.
52. Taskiran C, Erdem O, Onan A, Arisoy O, Acar A, Vural C, Erdem M, Ataoglu O, Guner H: The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 2006;16:1789-1793.
53. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51:268-275.
54. Yang LY, Lu WQ, Huang GW, Wang W: Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 2006;6:110.
55. Yao Y, Kubota T, Takeuchi H, Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 2005; 25:201-206.
56. Darland DC, D'Amore PA: Blood vessel maturation: vascular development comes of age. J Clin Invest 1999; 103:157-158.
57. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM: Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003; 162:183-193.
58. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshet E: Conditional switching of VEGF provides new insights into adult neovasculariza-tion and pro-angiogenic therapy. EMBO J 2002;21:1939-1947.
59. McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, Ellis LM: Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003;9:53-58.
60. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM: Induction of VEGF in perivascular cells defines a potential para-crine mechanism for endothelial cell survival. FASEB J 2001;15:1239-1241.
61. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-1393.
62. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004; 96:1473-1477.
63. Bove R, Char DH: Nondiagnosed uveal melanomas. Ophthalmology 2004; 111:554-557.
64. Damato B: Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt 2001;21:268-271.
65. Eskelin S, Kivela T: Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol 2002;86:333-338.